

Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Lead Product(s) : Urokinase
Therapeutic Area : Nephrology
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Urokinase is a Enzyme drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Kidney Failure, Chronic.
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
January 31, 2025
Lead Product(s) : Urokinase
Therapeutic Area : Nephrology
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Urokinase
Therapeutic Area : Hematology
Study Phase : Approved FDF
Sponsor : Sequel Pharma
Deal Size : $35.0 million
Deal Type : Agreement
Microbix Secures Funded Drug Commercialization Agreement
Details : The Agreement provides for Sequel to fund and undertake the necessary work to return Kinlytic (urokinase), a thrombolytic agent obtained from human neonatal kidney cells grown in tissue culture, to the U.S. for the clinical indication of venous catheter ...
Product Name : Kinlytic
Product Type : Enzyme
Upfront Cash : Undisclosed
May 16, 2023
Lead Product(s) : Urokinase
Therapeutic Area : Hematology
Highest Development Status : Approved FDF
Sponsor : Sequel Pharma
Deal Size : $35.0 million
Deal Type : Agreement

Details : Urokinase is a Enzyme drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Diabetic Foot.
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
July 11, 2012
